

**Cost-effectiveness of apixaban in non-valvular atrial fibrillation (NVAf)  
based on effectiveness data from a Spanish study in clinical practice  
(Real-World Evidence)**


**SUPPLEMENT 1.** FANTASIIA registry: Baseline clinical characteristics [9].

<b>Item</b>	<b>Acenocumarol</b> N=1,645	<b>DOAC</b> N= 533
Female sex, n (%)	719 (43.7)	246 (46.2)
Age (years), median (IQR)	74 (72-79)	73 (71-78)
<i>Comorbidities, n (%)</i>		
Hypertension	1,327 (80.7)	425 (79.7)
Diabetes mellitus	490 (29.8)	145 (27.2)
Heart failure	507 (30.8)	120 (22.6)
Previous stroke	258 (15.7)	113 (20.9)
<i>Renal disease, n (%)</i>		
CrCl < 50 ml/min	347 (21,1)	72 (13.5)
CHADS <sub>2</sub> mean $\pm$ SD	2.3 $\pm$ 1.2	2.2 $\pm$ 1.3
Discontinuation rate, %	4.6%	2.6%
Follow-up	2.5 years	2.5 years


CHADS<sub>2</sub>: Congestive Heart Failure, Hypertension, Age, Diabetes, Previous Stroke scale; CrCl: Creatinine Clearance; DOAC: direct-acting oral anticoagulant; IQR: Interquartile range; SD: standard deviation.

**SUPPLEMENT 2. Sensitivity analyses: Tornado diagrams.**


**A)**




**B)**




C)





D)




E)




EV: expected value (€/QALY gained); ICER: incremental cost-effectiveness ratio; WTP: Willingness to pay (€/QALY gained). Please note that decimal separators appearing in Figures A-E as commas are equivalent to periods in English notation.

**SUPPLEMENT 3.** Cost-effectiveness plane.**A)****B)**


C)



D)



E)



ICE: incremental cost-effectiveness; WTP: Willingness to pay (€/QALY gained).

Please note that the thousands separators appearing in Figures A-E as periods are equivalent to commas in English notation.